Melanoma
Feature
Are oncologists ready to confront a second wave of COVID-19?
From the Journals
Survey of Mohs surgeons highlights its use in invasive melanoma
“Mohs surgeons who previously treated MIS with MMS may be increasingly doing so and/or expanding their scope of treatment to include invasive...
Conference Coverage
Clinical factors and treatment tied to COVID-19 mortality in cancer patients
Analyses of CCC19 data revealed factors linked to mortality in patients with COVID-19 and cancer.
Clinical Insights
The scope of under- and overtreatment in older adults with cancer
From the Journals
Cancer disparities: One of the most pressing public health issues
“The burden of cancer is not shouldered equally by all segments of the U.S. population,” the AACR states.
Conference Coverage
Lenvatinib combo may offer hope after immunotherapy in melanoma
Conference Coverage
Survey quantifies COVID-19’s impact on oncology
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.
Clinical Insights
COVID-19 prompts ‘democratization’ of cancer trials
Dr. Alan Lyss reviews a panel discussion about how COVID-19 has affected cancer research.
From the Journals
Hair dye and cancer study ‘offers some reassurance’
From the Journals
Durable response 5 years after adjuvant combo in melanoma
Plateaus observed with relapse and distant metastasis-free survival suggest that true disease cures are being achieved with treatment.
From the Journals
Fatal pediatric melanomas diverse in presentation
One-fourth of fatal pediatric melanomas arose in association with congenital melanocytic nevi.